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creativecommons.org/licenses/by-nc-nd/Abstract Aim of the study: Melanoma subtypes have different aetiological characteristics.
Child height is positively associated with adult melanoma; however, a clarification of associ-
ations with specific melanoma variants is necessary for an improved understanding of risk fac-
tors underlying the histologic entities. This study investigated associations between childhood
height and future development of cutaneous melanoma variants.
Method: A cohort study of 316,193 individuals from the Copenhagen School Health Records
Register, with measured heights at ages 7e13 years who were born from 1930 to 1989. Mel-
anoma cases were identified via linkage to the national Danish Cancer Registry and subdi-
vided into subtypes. Cox proportional hazards regressions were performed.
Results: A total of 2223 cases of melanoma distributed as 60% superficial spreading melanoma
(SSM), 27.5% melanoma not otherwise specified (NOS), 8.5% nodular melanoma (NM), and
2% lentigo maligna melanoma (LMM). The remaining rare melanoma forms were not ana-
lysed. Childhood height was positively and significantly associated with SSM, melanoma
NOS, and NM, but not LMM, in adulthood. Per height z-score at age 13 years, the hazard
ratios were 1.20 (95% confidence intervals [CI]: 1.13e1.27) for SSM, 1.19 (95% CI: 1.09
e1.29) for melanoma NOS, and 1.21 (95% CI: 1.04e1.41) for NM. Further, growth patterns
were linked to the melanoma variants with persistently tall children having an increased risk of
developing SSM, melanoma NOS, or NM.eventive Medicine, Frederiksberg Hospital, Hovedvejen, Entrance 5, 1st Floor, Nordre Fasanvej 57, 2000
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K.D. Meyle et al. / European Journal of Cancer 67 (2016) 99e105100Conclusion: Childhood height is positively associated with the majority of the melanoma var-
iants. These results suggest that the underlying processes contributing to childhood height and
growth patterns interconnect early-life events with the predisposition to melanomagenesis in
adulthood.
ª 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Melanoma is one of the most rapidly increasing human
malignancies in populations of Caucasian descent [1].
Since both young and old individuals are affected by this
cancer form, it places a substantial economic burden on
societies [2].
Melanoma is subdivided into histopathological sub-
types, with the most common being superficial spreading
melanoma (SSM), nodular melanoma (NM), lentigo
maligna melanoma (LMM), and acral lentiginous mel-
anoma (ALM) [3]. Histologic subdivisions are based on
differences in cytological and architectural features,
growth patterns and, to some extent, the site on the
body [4]. The subtypes are important for aetiological
and diagnostic purposes, but not necessarily for prog-
nosis as this often depends on the lesion thickness [5].
Genetic vulnerability is known to prime certain in-
dividuals for melanomagenesis [6]. Moreover, sun
exposure, nevi count, and a fair pigmentation phenotype
can increase susceptibility to melanoma; however, their
significance differs among the subtypes [7].
Previously, we found that children who were one
height z-score taller than their peers had approximately
a 20% higher risk of developing adult melanoma in a
population of Danish schoolchildren [8]. This suggests
that mechanisms regulating childhood height may also
contribute to melanoma development in adulthood.
Nonetheless, it remains unknown if the future risk of
specific melanoma variants is related to height in
childhood. Therefore, this study investigated whether
childhood height was associated with the risk of
morphologically different cutaneous melanoma variants
in adulthood by analysing data from the same Danish
cohort of children.
2. Methods
2.1. Study population
In the Copenhagen municipality, physicians and nurses
annually measured the height and weight of Danish
children who attended public and private schools. These
measurements are contained in the electronic Copen-
hagen School Health Records Register, including in-
formation on body size on 372,636 Danish children,
born from 1930 to 1989 [9]. Information exists for eachchild from the ages of 7e13 years until 1983 as subse-
quently the children were only measured at school entry
and exit. Using the Lamda Mu Sigma method [10],
height was converted into z-scores according to age-,
sex- and birth cohort-specific (5-year interval)
references.
Since April 2, 1968, all Danish citizens have been
assigned a personal identification number [11], enabling
record linkages to national health registers. One is the
national Danish Cancer Registry which was established
in 1942 and contains information on malignancies [12].
Until 1994, the Danish Cancer Registry classified can-
cers using the International Classification of Diseases
(ICD) version 7 and thereafter according to ICD-10. In
the period of 1978e2004, the first version of the Inter-
national Classification of Diseases for Oncology (ICD-
O-1) was used followed by the third version (ICD-O-3)
to describe cancer morphology. In 2004, the Danish
Cancer Registry was modernised and cancers diagnosed
from 1978 to 2004 were converted into ICD-10 and
ICD-O-3 [12].
In this study, the identification numbers were used to
identify melanoma cases according to ICD-10 (C43) and
they were subdivided into histological categories in
agreement with ICD-O-3: SSM (8743), NM (8721),
ALM (8744), LMM (8742), and melanoma not other-
wise specified (NOS) (8720). The variants were analysed
separately, and individuals with other forms of mela-
noma were censored. Vital status for each individual
was obtained from the Danish Civil Registration System
[11].
Follow-up began on January 1, 1978, or age 15 years,
whichever came later. From an initial population of
372,636 individuals, we excluded individuals who did
not have an identification number (N Z 42,668), who
were deceased, emigrated, or lost to follow-up prior to
January 1, 1978, or before age 15 years (NZ 7628), who
were diagnosed with melanoma prior to 1978 (N Z 96)
or before age 15 years (N Z 5), who were missing the
date at melanoma diagnosis (N Z 4) or missing height
or weight values at all ages (N Z 6033) or who had
outlying measures of height or body mass index (kg/m2)
(z-score <4.5 or >4.5) at all ages (NZ 9), resulting in
an eligible cohort of 316,193 individuals (160,013 men,
156,180 women) (Supplementary Fig. 1).
In analyses investigating associations between change
in height and the melanoma variants, we only included
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years (total 254,499; 127,717 men, 126,782 women).
Follow-up ended on the date of a melanoma diag-
nosis, emigration, death, loss to follow-up, or December
31, 2012 (date of the last available update from the
Danish Cancer Registry), whichever came first.
2.2. Statistical methods
Associations between childhood height z-scores and the
different melanoma variants were assessed using Cox
proportional hazards regressions with age as the un-
derlying time metric. Associations between growth pat-
terns in height z-scores from the ages of 7e13 years and
the melanoma variants were examined using the same
approach. Analyses were stratified by birth cohort (5-
year intervals: 1930e1934,., 1985e1989). The linearity
of the associations was investigated by testing against a
restricted cubic spline (five knots). The proportional
hazard assumption was examined by modelling a time-
varying effect in the Cox regression model. Potential
interactions between height and either birth cohort
(1930e1934,., 1955e1989) or sex on associations with
the melanoma variants were assessed using likelihood
ratio tests. We detected no signs of departures from
linearity, violations of the proportional hazards as-
sumptions, or birth cohort effects. Significant differ-
ences were not detected between the sexes (all P > 0.11);
thus, all analyses were stratified by sex. The statistical
analyses were conducted using Stata (version 12.1). The
study was approved by the Danish Data Protection
Agency. In accordance with Danish law, informed
consent is not required for purely register-based studies
of preexisting information.
3. Results
During 9.1 million person-years of follow-up, 2223 cases
of melanoma were identified (1018 men, 1205 women).
Most melanoma cases were categorised as SSM (60%)
with the remaining cases being melanoma NOS (27.5%),
NM (8.5%), LMM (2%), ALM (0.6%), and other rare
melanoma forms (1.5%). The melanoma variants were
similarly distributed in men and women, but the medianTable 1
Distribution and median age at diagnosis (years) of the morphologically d
Morphology N cases (%)a
Men Women
SSM 588 (57.8) 745 (61.8)
Melanoma NOS 291 (28.6) 321 (26.6)
NM 104 (10.2) 84 (7.0)
LMM 17 (1.7) 27 (2.2)
ALM 6 (0.6) 7 (0.6)
Abbreviations: ALM, acral lentiginous melanoma; LMM, lentigo malign
SSM, superficial spreading melanoma.
a The percentages were calculated from the total population of 2223 m
numbers do not add to 100%.age at diagnosis varied by morphology and sex, ranging
from 51 to 67 years (Table 1). Due to the limited number
of cases, ALM and the rare melanomas were not
investigated further.
At ages 7e13 years, one increase in height z-score
was positively associated with SSM, melanoma NOS,
and NM in adulthood (Fig. 1, Supplementary Tables
1e3). To put these associations into perspective, one
z-score in height at age 13 years corresponds to
approximately 8 cm in boys and 6.9 cm in girls. For the
LMM subtype, the hazard ratios (HRs) at ages 7e13
years were in the positive direction, but only borderline
statistically significant at 8 years (Fig. 1, Supplementary
Table 4).
In the analyses investigating if growth patterns of
height in children from 7 to 13 years were associated
with the various melanomas in adulthood, we conducted
separate analyses including 1172 SSM cases (509 men,
663 women), 519 melanoma NOS cases (249 men, 270
women), 165 NM cases (92 men, 73 women), and 42
LMM cases (16 men, 26 women). As few children
changed 1 z-score in height between the ages of 7 and
13 years, the effects of change per 0.5 z-score were
analysed. Compared with an average child (reference: z-
score 0 at both ages 7 and 13), a child who was tall at 7
years, but average height at 13 years (z-score 0.5 at 7
years and z-score 0 at 13 years) had a significantly
increased risk of developing SSM (P Z 0.015) or mel-
anoma NOS (P Z 0.009) (Table 2). Compared with the
average child, a child who was persistently tall at 7 and
13 years (z-score 0.5 at 7 years and z-score 0.5 at 13
years) had significantly higher risk of developing SSM
(P < 0.001), melanoma NOS (P < 0.001), or NM
(P Z 0.010) (Table 2). However, in comparison to the
average child, a child who was average at 7 years but tall
at 13 years (z-score 0 at 7 years and z-score 0.5 at 13
years) did not have a significantly increased risk of
developing any of the examined melanoma variants
(Table 2). A comparison between children who grew tall
between 7 and 13 years and children who were persis-
tently tall revealed that the persistently tall children had
significantly higher risks of developing SSM (HR 1.07,
95% confidence intervals [CI]: 1.01e1.14, PZ 0.015) or
melanoma NOS (HR 1.12, 95% CI: 1.03e1.22,ifferent melanoma variants.
Median age at diagnosis (years) (5the95th percentiles)
Men Women
58.4 (33.1e74.2) 52.8 (28.5e73.7)
56.9 (35.0e75.4) 51.9 (27.8e71.6)
58.9 (34.0e75.3) 56.8 (31.8e76.2)
67.7 (60.9e77.1) 64.8 (44.7e75.5)
62.1 (41.0e77.2) 66.7 (53.0e73.8)
a melanoma; NM, nodular melanoma; NOS, not otherwise specified;
elanoma cases (including the rare melanomas), explaining why the
Fig. 1. Hazard ratios and 95% confidence intervals for the risk of developing SSM, melanoma NOS, NM, and LMM per unit height z-
score at the ages 7, 10, and 13 years. All analyses were stratified by sex and 5-year birth cohorts. CI, confidence interval; LMM, lentigo
maligna melanoma; NM, nodular melanoma; NOS, not otherwise specified; SSM, superficial spreading melanoma.
Table 2
Growth in height between 7 and 13 years of age and HRs (95% CI) for adult melanoma variants.
Height z-scorea,b SSM Melanoma NOS NM LMM
7 years 13 years HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
0 0 Reference Reference Reference Reference
0.5 0 1.07 (1.01e1.14) 1.12 (1.03e1.22) 1.05 (0.90e1.23) 1.08 (0.79e1.46)
0 0.5 1.03 (0.97e1.09) 0.98 (0.90e1.07) 1.06 (0.91e1.23) 1.04 (0.77e1.41)
0.5 0.5 1.10 (1.07e1.14) 1.10 (1.05e1.15) 1.11 (1.03e1.20) 1.12 (0.95e1.31)
Abbreviations: CI, confidence interval; HR, hazard ratio; LMM, lentigo maligna melanoma; NM, nodular melanoma; NOS, not otherwise
specified; SSM, superficial spreading melanoma.
a All analyses were stratified by sex and 5-year birth cohorts.
b The reference child has a height z-score of 0, a ‘taller’ child has a z-score of 0.5, and a ‘persistently taller’ child has a z-score of 0.5 at both age 7
years and 13 years.
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P Z 0.527) or LMM (HR 1.08, 95% CI: 0.79e1.46,
P Z 0.636).4. Discussion
In this study, taller childhood height was positively
associated with developing SSM, melanoma NOS and
NM, but not LMM, in adulthood. Height trajectories in
childhood were associated with melanoma variants.
Specifically, persistently tall children had significantly
increased risks of developing SSM, NM or melanoma
NOS when compared with average height children, and
SSM or melanoma NOS when compared to children
who grew tall between age 7 and 13 years.
In the present study, the associations between child-
hood height and the SSM, NM, and melanoma NOS
variants were similar to the height-melanoma associa-
tions we previously reported for all subtypes combined[8]. Although the height-LMM associations were posi-
tive, they were not statistically significant, likely because
of a lack of power due to the small number of LMM
cases (N Z 44). Collectively, these results demonstrate
that childhood height is an indicator of risk for several
melanoma variants and does not only reflect a height-
melanoma association driven by the predominant sub-
type of SSM.
In our study, 27.5% of the melanomas were classified
as melanoma NOS, and this is as expected [13].
Recently, fewer melanomas are classified as NOS (3.6%
of melanomas in 2014) [14], likely resulting from the
addition of diagnostic categories and fewer centres
conducting histopathological examinations, reflecting
that more tumours are categorised in greater detail than
before. It is therefore likely that most of the melanoma
NOS tumours in our study would be classified today as
one of the most frequent melanoma types and only a
small subset would be other rare tumour forms (des-
moplastic melanoma, clear cell melanoma etc.).
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parable with results for SSM and NM; the two most
common forms in this study.
We found that height growth patterns in childhood
were differently associated with the melanoma variants.
Children who were tall at the age of 7 years had
significantly increased risks of SSM and melanoma
NOS, whereas persistently tall children had increased
risks of SSM, melanoma NOS, and NM. These results
suggest that tall stature at 7 years and/or persistent
tallness at 7 and 13 years are indicators of risk for
melanomagenesis in adulthood. Since our cohort does
not include children younger than 7 years of age, we are
unable to explore the possibility that even younger ages
are of particular importance for future melanoma
predisposition.
Comparisons with other studies are challenging as
most have not investigated childhood height, and this is
presumably due to a lack of appropriate data resources.
A large body of adult literature supports associations
between height and melanomagenesis; however, these
studies did not subcategorise melanoma according to
morphology and considered the disease as one biological
entity [15e24]. Nonetheless, a separation of melanoma
into histological subtypes suggests that tall adults are
predisposed to the development of SSM but not NM
and LMM [25]. Given our findings and that melanoma
development occurs over a period of 20e40 years [26],
these results indicate that the susceptibility to this dis-
ease already originates in childhood. Although it has
been suggested that melanoma mortality will decrease in
the near future due to changes in sun habits among
children [27], the lack of birth cohort effects in the
present study suggests that the height-melanoma asso-
ciations reflect biological mechanisms that have
remained stable across time.
The mechanisms interconnecting height and cancer
are not well understood; however, they likely act
cooperatively during the complex manifestation of
carcinogenesis. It is possible that height is a biomarker
for other underlying processes affecting both stature
and cancer development. A recent large-scale study
identified almost 700 genetic variants that are respon-
sible for approximately 20% of the heritability for
height [28]. It can be speculated that some of these ge-
netic variants also affect malignant transformation.
Moreover, a recent study found a positive association
between height and nevi count which is known to be a
strong risk factor for melanoma development [29].
Another postulated height-melanoma mechanism is
that taller individuals have an increased risk of cancer
because of a greater number of cells and thus a higher
rate of cell divisions within tissues [30]. In accord with
this hypothesis, the proliferation of melanocytes accel-
erates during childhood [31], increasing the number of
cells capable of acquiring detrimental lesions that could
predispose children to future melanoma development.Notably, a site-dependent susceptibility to melanoma-
genesis has been suggested [32], indicating that partic-
ular body areas are more vulnerable for malignant
transformation. With regards to the association be-
tween height and melanoma, studies that investigated
the anatomical site distribution of melanomas found
that the lesions occur mainly on the trunk in men and
on the lower extremities in women [33e38], although
there are recent indications that women are starting to
exhibit more centrally located tumours [39]. The diverse
localisation of melanomas has been linked to different
sun exposure patterns and sunscreen use between the
sexes [37,38]. However, children already display a sex-
specific spreading of nevi that is similar to the mela-
noma distribution in adults, suggesting that the loca-
tion of melanoma could be influenced by other factors
in addition to differences in sun exposure [40e42]. It
may also be speculated whether the distribution of nevi
is interconnected with sex-specific height growth pat-
terns during childhood. Boys and girls exhibit distinct
growth patterns where diverse body parts grow at
different time points. In girls, the peak height velocity
occurs between the peak of leg and trunk length ve-
locities, whereas the peak height velocity in boys is
closer to the peak of trunk length growth [43]. Hence,
the spurt in boys final height is mainly attributable to
an increase in trunk rather than leg length [43].
Accordingly, the sex-specific growth spurts during
childhood could potentially accelerate mitotic activity
and malignant transformation of melanocytes,
explaining why the trunk and legs might be more sus-
ceptible to melanoma development in men and women,
respectively.
The present study has several strengths including its
large size, its long follow-up with a minimal loss of in-
dividuals, and its inclusion of measured height values in
contrast with self-reported measurements. Moreover,
the unique design of the cohort enabled us to investigate
the effects of changes in height in childhood and their
associations with different melanoma variants in adult-
hood. However, the study may be limited by the lack of
information on particular height components (leg and
trunk length) and established melanoma risk factors
including genetic status, nevi count, pigmentation
phenotype, and sun habits.
In conclusion, childhood height is positively and
significantly associated with developing adult SSM,
melanoma NOS, and NM. Moreover, children’s height
patterns are linked with the risk of developing different
melanoma variants. These results suggest that childhood
height is an indicator of risk for the majority of mela-
noma variants and is not only a phenomenon restricted
to the predominant subtypes. Collectively, these results
expand the current knowledge of the underlying risk
factors for the different melanoma variants and
offer insight into the complex interplay between height
in childhood and future melanomagenesis.
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